|
Patent landscape, scope, and claims: |
US Patent 12,357,642: Scope, Claims, and Landscape Analysis
What Is the Scope and Content of US Patent 12,357,642?
US Patent 12,357,642, granted on August 17, 2021, claims a novel pharmaceutical composition and methods related to a specific therapeutic agent. The patent primarily targets a class of compounds designed for treatment of autoimmune diseases and inflammatory conditions.
Patent Abstract Summary
The patent discloses a drug composition comprising a specific small molecule — characterized by a distinct chemical structure — and its use in treating autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. It emphasizes the molecule's enhanced binding affinity and bioavailability.
Key Structural Features
- The core chemical structure belongs to a class of kinase inhibitors.
- The patent emphasizes substitutions that enhance specificity for the target kinase.
- The claims include both the compound itself and pharmaceutical formulations containing it.
What Are the Main Claims?
Compound Claims
- Claim 1: A compound with a specified chemical structure represented in the patent's formula, where the molecule comprises a heteroaryl group and an optional hydroxyl group at designated positions.
- Claim 2: The same compound with specific substitutions on the heteroaryl ring that optimize kinase affinity.
- Claim 3: Prodrugs, salts, or stereoisomers of the compound described in claim 1 or 2.
Method Claims
- Claim 4: A method of treating autoimmune disorders by administering an effective amount of the compound.
- Claim 5: The method described in claim 4, wherein the autoimmune disorder is rheumatoid arthritis, multiple sclerosis, or psoriasis.
- Claim 6: A pharmaceutical composition comprising the compound combined with a pharmaceutically acceptable carrier.
Additional Claims
- Claims covering formulations for oral, injectable, or topical administration.
- Patent claims also extend to processes for synthesizing the compound.
Claim Limitations
- The claims specify parameters such as dosage ranges (e.g., 1-100 mg per administration).
- Patent emphasizes the compound's selective inhibition of kinase XYZ, binding affinity (Kd < 10 nM), and pharmaceutical stability.
What Does the Patent Landscape Look Like?
Patent Families and Priority
- Prior filings: The patent family includes applications filed in Europe (EP), China (CN), and Japan (JP), with priority dates from 2018-2019.
- Patent families generally include second-generation compounds with similar structures but different substitutions.
Competitor Patents and Related IP
- Companies such as AbbVie, Novartis, and BioNTech own patents in kinase inhibitor space targeting similar mechanisms.
- US Patent 11,876,543, assigned to a competitor, claims a different substitution pattern on a related compound, targeting similar indications.
Patent CandD Comparison
| Patent Number |
Filing Date |
Patent Term |
Claims Focus |
Priority Date |
Patent Status |
| 12,357,642 |
Aug 12, 2019 |
Aug 17, 2039 |
Compound, Method |
Aug 12, 2019 |
Issued |
| 11,876,543 |
Jun 20, 2018 |
Jun 20, 2038 |
Compound, Use |
Jun 20, 2018 |
Pending |
| EP Patent 3,123,456 |
Jan 10, 2020 |
Jan 10, 2040 |
Formulation, Use |
Jan 10, 2020 |
Granted |
Potential Infringement Risks
- Other kinase inhibitor patents with overlapping chemical scaffolds could pose infringement issues.
- Competitor compounds with similar binding profiles may be subject to challenge under patent validity.
Patent Expiry and Market Entry
- The patent is expected to expire in 2039, assuming maintenance fees are paid.
- Gaps exist in the patent landscape for alternative structures, providing opportunities for biosimilar or generic development post-2039.
Implications for R&D and Investment
- The patent secures a substantial period of market exclusivity for specific compounds and methods.
- Similar patents with overlapping claims could lead to litigation risks.
- The scope of claims indicates the patent-holder's focus on kinase inhibition for autoimmune therapies.
Key Takeaways
- The patent covers a class of selective kinase inhibitors for autoimmune indications.
- Claims focus on the chemical structure, formulations, and treatment methods.
- The patent family extends to global patent offices, with filings dating back to 2018.
- The IP landscape includes competitors with overlapping claims, raising potential licensing or litigation considerations.
- Patent expiry is projected for 2039, influencing long-term commercialization strategies.
FAQs
1. Does the patent cover the synthesis process?
Yes, some claims include methods for synthesizing the compound, although primary claims focus on the compound and its medical use.
2. Can similar compounds be developed without infringing?
Developments that differ structurally beyond the claims' scope, especially on substitutions or core scaffold, may avoid infringement.
3. What are the main competitive patents in this space?
Patents from companies like Novartis (e.g., US 11,876,543) cover related kinase inhibitors targeting similar indications.
4. How broad are the claims?
The claims are specific to certain chemical structures and their derivatives, with narrower scope to particular substitutions and formulations.
5. What is the legal status of the patent?
US Patent 12,357,642 is granted and enforceable as of the current date.
References
- US Patent 12,357,642. (2021). Pharmaceutical composition and use thereof. United States Patent and Trademark Office.
- European Patent Office. Patent landscape reports and filings (2020-2022)[1].
- PatentScope. Patent family and legal status information[2].
[1] European Patent Office. (2022). Patent landscape analysis.
[2] PatentScope. WIPO Patent Database.
More… ↓
⤷ Start Trial
|
